Pain Management

Pain Management

At Anesiva, we have dedicated ourselves to the development and commercialization of new therapies for pain management because we believe there is a significant unmet medical need for new treatment options in this area.

Current pain management options are often less than optimal given their limited efficacy, inconvenient administration, long onset of action, limited duration of activity, adverse reactions and/or tendency to cause physical dependence.

With increased competition among hospitals for patients, and increased focus on patient satisfaction to attract patients, we have found that many hospitals in the United States now strive to create “pain-free” environments, and reducing pain is quickly becoming a priority for hospital emergency departments. We believe that this creates a favorable environment for the adoption of our pain medicines.

In the links below, we provide more information regarding specific types of pain addressed by our product, Zingo™, and our most advanced clinical compound, Adlea™:

Zingo™ (lidocaine hydrochloride monohydrate) powder intradermal injection system:

Adlea™: